Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,125,000 shares o